Stockscreener 앱 받기
0.867
2.30%
0.0195
시간 외 거래:
.88
0.013
+1.50%
전일 마감가:
$0.8475
열려 있는:
$0.8475
하루 거래량:
242.78K
Relative Volume:
0.27
시가총액:
$26.77M
수익:
$680.00K
순이익/손실:
$-75.33M
주가수익비율:
-0.1401
EPS:
-6.1898
순현금흐름:
$-57.38M
1주 성능:
-1.77%
1개월 성능:
-33.82%
6개월 성능:
-51.02%
1년 성능:
-52.10%
1일 변동 폭
$0.8401
$0.8784
1주일 범위
$0.83
$0.9235
52주 변동 폭
$0.7365
$8.08
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
0.867 | 26.17M | 680.00K | -75.33M | -57.38M | -6.1898 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Rodman & Renshaw | Buy |
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BTAI|BioXcel Therapeutics Inc|Price:0.848|Chg%:-0.023 - TradingKey
BioXcel Therapeutics Inc (BTAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
BioXcel Therapeutics Inc|Price:0.848|Chg%:-0.023 - TradingKey
BioXcel Therapeutics Inc (BTAI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
[Latest] Global AI in Drug Repurposing Market Size/Share Worth USD 10.56 Billion by 2035 at a 23.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
BioXcel Therapeutics Q1 2026 Earnings: EPS Beats Estimates by 35.72% Amid Continued Cost ManagementShare Dilution Risk - dars.gov.et
BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
BioXcel Therapeutics (BTAI) Rallies 7.9% as Biotech Stock Tests Key Resistance at $0.92ALMA Signal - dars.gov.et
BioXcel Therapeutics (BTAI) Investor update Summary - Quartr
BioXcel Therapeutics (BTAI) Q1 2026 earnings summary - Quartr
BioXcel Therapeutics (BTAI) Registration Filing Summary - Quartr
BioXcel Therapeutics (BTAI) Q2 2024 earnings summary - Quartr
BioXcel Therapeutics (BTAI) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary - Quartr
BioXcel Therapeutics (BTAI) Q4 2025 earnings summary - Quartr
BTAI Q1 2026 Earnings: Narrowing Losses as EPS Surpasses Estimates Amid Pipeline ProgressROE Trend Analysis - Bölüm Sonu Canavarı
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
BioXcel (NASDAQ: BTAI) eases liquidity covenant and defers $9M loan payment - Stock Titan
BioXcel Therapeutics Amends Credit Agreement, Tightens Liquidity - TipRanks
BioXcel Therapeutics (BTAI) Holds Above $1.31 Support Amid Modest UptickFundamentals - dars.gov.et
BTAIBioXcel Therapeutics Inc Options - Finviz
Price to sales forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits
Price to sales forward of BioXcel Therapeutics, Inc. – MUN:BX20 - TradingView
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell 3000E Growth Benchmark - marketscreener.com
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell Microcap Index - marketscreener.com
BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell 3000E Index - marketscreener.com
BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
Price to earnings forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
Enterprise value to revenue forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
Enterprise value to EBITDA forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView
BioXcel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yocca Frank - Moomoo
BioXcel Therapeutics, Inc. Actuals & Estimates (FWB:BX20) - TradingView
BTAI Should I Buy - Intellectia AI
BioXcel Therapeutics, Inc. Actuals & Estimates (NASDAQ:BTAI) - TradingView
BioXcel Therapeutics, Inc. Actuals & Estimates (LSX:A40YSR) - TradingView
BTAI Forecast — Price Target — Prediction for 2027 - TradingView
BioXcel Therapeutics Inc. (BTAI) Q1 2026 Earnings: Surprise EPS Beat Drives Stock RallyEarnings Per Share - dars.gov.et
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
BioXcel Therapeutics Q1 2026 Earnings: EPS Beat Driven by Cost Controls Despite No RevenuePost-Announcement Reaction - Město Břeclav
BTAI Q1 2026 Earnings: EPS Beat Amid No Revenue; Stock Edges UpEarnings Growth Analysis - dars.gov.et
BioXcel Therapeutics (NASDAQ: BTAI) officer converts RSUs into Common Stock - Stock Titan
BioXcel (BTAI) CEO exercises 219 RSUs and reports major indirect stakes - Stock Titan
BioXcel Therapeutics (BTAI) CSO converts 35 RSUs, now holds 26,210 shares - Stock Titan
BioXcel (BTAI) CFO gains 35 shares as 212 RSUs remain - Stock Titan
BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioXcel Therapeutics Inc (BTAI) Valuation: PE, PB & Fair Value Analysis - TradingKey
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.30%
2.01%
자본화:
|
볼륨(24시간):